References
- WHO/HTM/TB/2015.22. Global tuberculosis report. 2015. Geneva (Switzerland): World Health Organization, 2015.
- Uplekar M, Weil D, Lonnroth K, et al. WHO’s new end TB strategy. Lancet [Internet]. 2015;385(9979):1799–1801.
- Roy A, Eisenhut M, Harris RJ, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ. 2014;349(5):g4643.
- Tuberculosis Vaccine Initiative (TBVI). Pipeline of Vaccines. 2015. Available from: http://www.tbvi.eu/what-we-do/pipeline-of-vaccines/
- Ndiaye BP, Thienemann F, Ota M, et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2015;3(3):190–200.
- Tameris MD, Hatherill M, Landry BS, et al. Safety and effi cacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG : a randomised, placebo-controlled phase 2b trial. Lancet. 2013;381(9871):1021–1028.
- Frick M, Treatment Action Group. 2015 Report on tuberculosis research funding trends, 2005-2014. New York (NY): Treatment Action Group (TAG); 2015. Available from: http://www.treatmentactiongroup.org/sites/g/files/g450272/f/201511/TB_FUNDING_2015_WEB.pdf
- STOP TB Partnership. The Global Plan to Stop TB (2011-2015) [Internet]. 2010. Available from: http://stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011-2015.pdf
- Rustomjee R, McClain B, Brennan MJ, et al. Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents. Tuberculosis (Edinb). 2013;93(2):136–142.
- Gröschel MI, Prabowo SA, Cardona P-J, et al. Therapeutic vaccines for tuberculosis–a systematic review. Vaccine [Internet]. 2014;32(26):3162–3168.
- Brennan MJ, Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb). 2012;92(Suppl 1):S6–13.
- Bertholet S, Ireton GC, Ordway DJ, et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med. 2010;2(53):53ra74.
- Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med. 2011;17(2):189–194.
- Hawn TR, Day TA, Scriba TJ, et al. Tuberculosis vaccines and prevention of infection. Microbiol Mol Biol Rev. 2014;78(4):650–671.
- Ellis RD, Hatherill M, Tait D, et al. Innovative clinical trial designs to rationalize TB vaccine development. Tuberculosis (Edinb). 2015;95(3):352–357.
- Wood R, Liang H, Wu H, et al. Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int J Tuberc Lung Dis. 2010;14(4):406–412.
- Kaufmann SHE, Evans TG, Hanekom WA. Tuberculosis vaccines: time for a global strategy. Sci Transl Med. 2015;7(276):276fs8.
- Minassian AM, Satti I, Poulton ID, et al. A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin. J Infect Dis. 2012;205(7):1035–1042.
- Knight GM, Griffiths UK, Sumner T, et al. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci U S A. 2014;111(43):15520–15525.
- Karp CL, Wilson CB, Stuart LM. Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool. Immunol Rev. 2015;264(1):363–381.